Merck’s Stromectol (Ivermectin) Used in Hungarian Clinical Trial Targeting Mild Cases
During Worst Pandemic Spike in Eastern Europe Earlier this month,
the Eastern European nation of Hungary’s National Institute of Pharmacy
and the European Medicines Agencyauthorized a clinical trial using Merck’s Stromectol, a brand of ivermectin in a clinical trial targeting mild COVID-19 cases here.
The sponsor of this study now, Meditop Pharmaceutical Ltd.,
targets 70 participants for this randomized, double-blind, placebo-controlled study
to assess the safety and efficacy of ivermectin in asymptomatic and mild severity COVID-19 patients.
It is also supported by contract research organization (CRO) Cortex Pharma Services.
Conducted at three (3) trial site locations, the study is planned to commence for a few months and occurs in the middle of the worst pandemic spike this nation has yet experienced.
Hungary’s rate of COVID-19 infection
has doubled since its worst spike in November due to the UK variant of SARS-CoV-2.
Eastern European nations aren’t necessarily as rich as those in the West,
perhaps that’s why already ivermectin has been authorized in
Slovakia,
Macedonia、
Bulgaria.The Czech Republic
has authorized limited procurement by hospitals for compassionate use.Will Hungary be next?